Abstract

Immunogens inducing protective, disease-sparing CD8+ T cell responses are a primary focus of research efforts at the VRC. DNA vaccines are the chief platform of vaccine candidates currently. While DNA immunogens can generate CD8+ CTL responses, administration of large quantities of DNA is required to induce immunity. These studies are designed to identify interventions that will increase the efficiency of DNA immunization and to optimize the conditions of each intervention. With the identification of procedures that increase the uptake and/or expression of vaccine DNA, the administration of less DNA would be required, making the use of DNA vaccines more widely applicable, particularly in developing countries. Additionally, vector-based immunogens expressing matched codon-modified viral proteins will be evaluated for their relative abilities to induce virus-specific immune responses. Specifically, the magnitude and the quality of the immune responses induced by each vector will be compared using murine prime-challenge models.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIAAI005061-08
Application #
8148437
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
2010
Total Cost
$443,301
Indirect Cost

  Institution

Name
National Institute of Allergy and Infectious Diseases
Department
Type
DUNS #
City
State
Country
Zip Code

  Publications

Liang, Bo; Ngwuta, Joan O; Surman, Sonja et al. (2017) Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate. J Virol 91:
Liang, Bo; Ngwuta, Joan O; Herbert, Richard et al. (2016) Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector. J Virol 90:10022-10038
Graham, Barney S; Modjarrad, Kayvon; McLellan, Jason S (2015) Novel antigens for RSV vaccines. Curr Opin Immunol 35:30-8
Kines, Rhonda C; Zarnitsyn, Vladimir; Johnson, Teresa R et al. (2015) Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles. PLoS One 10:e0120797
Correia, Bruno E; Bates, John T; Loomis, Rebecca J et al. (2014) Proof of principle for epitope-focused vaccine design. Nature 507:201-6
Johnson, Teresa R; Rangel, David; Graham, Barney S et al. (2014) Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. Mol Ther 22:196-205
McLellan, Jason S; Chen, Man; Leung, Sherman et al. (2013) Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340:1113-7
Graham, Barney S (2013) Advances in antiviral vaccine development. Immunol Rev 255:230-42
McLellan, Jason S; Chen, Man; Joyce, M Gordon et al. (2013) Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342:592-8
Graham, Barney S; Anderson, Larry J (2013) Challenges and opportunities for respiratory syncytial virus vaccines. Curr Top Microbiol Immunol 372:391-404

Showing the most recent 10 out of 18 publications